# The Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients

Study · id `cardio:ct-nct04028544` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04028544](<https://clinicaltrials.gov/study/NCT04028544>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04028544

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 5380 participants.

## Technical summary

Registry record NCT04028544. Randomized; quadruple masking; primary purpose treatment. Start 2019-03-26 (actual); primary completion 2020-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 5380 participants (planned count; ClinicalTrials.gov record NCT04028544, source copy `cardio:ctgov-nct04028544-2019-07-22`, retrieved 2026-10-26)
- Started: 2019-03-26 (actual) (ClinicalTrials.gov record NCT04028544, source copy `cardio:ctgov-nct04028544-2019-07-22`, retrieved 2026-10-26)
- Primary completion: 2020-09 (anticipated) (ClinicalTrials.gov record NCT04028544, source copy `cardio:ctgov-nct04028544-2019-07-22`, retrieved 2026-10-26)
- Completion: 2021-09 (anticipated) (ClinicalTrials.gov record NCT04028544, source copy `cardio:ctgov-nct04028544-2019-07-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04028544, source copy `cardio:ctgov-nct04028544-2019-07-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04028544-2019-07-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients
- Condition: Heart Failure
- Intervention (Drug): Qishenyiqi dropping pills
- Intervention (Drug): Placebo
- Lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
- Lead sponsor class: OTHER
- Collaborator: Tianjin Tasly Pharmaceutical Co., Ltd
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital (`cardio:org-chinese-academy-of-medical-sciences-fuwai-hospital`)

## Provenance

Content hash: a86e4379eaa2235f248c0f38f2af16c2d310ae102a6660dcf442bca297d57c47
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
